PMID- 35966743
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220816
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2022
DP  - 2022
TI  - Influence of Lacidophilin Vaginal Capsules plus rh-IFN-alpha2b on Efficacy, Vaginal 
      Microecology, and Safety of Patients with HPV Infection.
PG  - 3632053
LID - 10.1155/2022/3632053 [doi]
LID - 3632053
AB  - BACKGROUND: Human papillomavirus (HPV) is a self-limiting disease, and there is 
      no specific antiviral drug at present. PURPOSE: Here, we analyzed the influence 
      of lacidophilin vaginal capsules plus recombinant human interferon alpha-2b 
      (rh-IFN-alpha2b) on efficacy, vaginal microecology, and safety of patients with HPV 
      infection. Two hundred cases of HPV infection admitted between January 2019 and 
      December 2020 were retrospectively collected. Of them, 90 cases receiving 
      rh-IFN-alpha2b intervention were assigned to the control group (CG), and 110 cases 
      given lacidophilin vaginal capsules in addition to rh-IFN-alpha2b were included in 
      the research group (RG). Baseline data, efficacy, vaginal microecology, 
      microecological restoration recovery, and incidence of adverse events (AEs) were 
      compared between the two groups. RESULTS: The analyses revealed nonsignificant 
      difference in baseline data between RG and CG, indicating comparability. In terms 
      of efficacy, RG showed a statistically higher negative conversion ratio (NCR) 
      than CG (57.27% vs. 47.78%), as well as an obviously higher overall response rate 
      (ORR) (90.90% vs. 72.22%). As far as the vaginal microecology was concerned, the 
      incidence rates of catalase-positive, sialidase-positive, abnormal microbial 
      density, and abnormal microbial diversity of RG were significantly lower compared 
      with CG, but no evident differences were determined in Trichomonas 
      vaginalis-positive and Candida-positive. As for microecological restoration, RG 
      had an obviously higher vaginal microecological recovery rate than CG (90.00% vs. 
      65.56%), as well as notably lower vaginal secretion pH and Nugent score. On the 
      other hand, RG and CG showed no statistical significance in the incidence of AEs 
      (12.73% vs. 13.33%). CONCLUSIONS: The main contributions of this study are as 
      follows: first, it is confirmed that lacidophilin vaginal capsules plus 
      rh-IFN-alpha2b has better clinical effects than rh-IFN-alpha2b alone in HPV-infected 
      patients; second, it demonstrates that the combination therapy can significantly 
      improve NCR and ORR, without increasing the incidence of AEs, and is beneficial 
      to improve patients' vaginal microecology and promote its restoration from the 
      multidimensional aspects of efficacy, safety, and vaginal microecology and its 
      recovery. Our findings provide valuable clinical evidence for the drug treatment 
      of HPV-infected patients.
CI  - Copyright (c) 2022 Yan Sun et al.
FAU - Sun, Yan
AU  - Sun Y
AD  - Obstetrics and Gynecology, Xishan People's Hospital of Wuxi City, Wuxi 214000, 
      Jiangsu, China.
FAU - Xu, Jianqun
AU  - Xu J
AD  - Obstetrics and Gynecology, Xishan People's Hospital of Wuxi City, Wuxi 214000, 
      Jiangsu, China.
FAU - Zhou, Hongya
AU  - Zhou H
AD  - Obstetrics and Gynecology, Xishan People's Hospital of Wuxi City, Wuxi 214000, 
      Jiangsu, China.
FAU - You, Lina
AU  - You L
AD  - Obstetrics and Gynecology, Xishan People's Hospital of Wuxi City, Wuxi 214000, 
      Jiangsu, China.
FAU - Zhu, Yan
AU  - Zhu Y
AUID- ORCID: 0000-0001-9810-8543
AD  - Obstetrics and Gynecology, Xishan People's Hospital of Wuxi City, Wuxi 214000, 
      Jiangsu, China.
LA  - eng
PT  - Journal Article
DEP - 20220803
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC9365531
COIS- The authors declare that there are no conflicts of interest.
EDAT- 2022/08/16 06:00
MHDA- 2022/08/16 06:01
PMCR- 2022/08/03
CRDT- 2022/08/15 03:46
PHST- 2022/06/05 00:00 [received]
PHST- 2022/07/09 00:00 [accepted]
PHST- 2022/08/15 03:46 [entrez]
PHST- 2022/08/16 06:00 [pubmed]
PHST- 2022/08/16 06:01 [medline]
PHST- 2022/08/03 00:00 [pmc-release]
AID - 10.1155/2022/3632053 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2022 Aug 3;2022:3632053. doi: 
      10.1155/2022/3632053. eCollection 2022.